Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wang, Quan ^a   Wei, Feng ^a   Li, Chunsheng ^b   Lv, Guoyue ^a   Wang, Guangyi ^a   Liu, Tongjun ^b   Bellail, Anita C ^c   Hao, Chunhai ^c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84882737154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073175     Document Type: Article

References (69)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
2. Kim DD, Eng C, (2012) The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs 21: 1775-1788. doi:10.1517/13543784.2012.721353. PubMed: 22978346.
3. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484. doi:10.1016/j.cell.2006.01.016. PubMed: 16469695.
4. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35. doi:10.1038/nrm3025. PubMed: 21157483.
5. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189. doi:10.1016/S0092-8674(02)00833-4. PubMed: 12150926.
6. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302. doi:10.1016/j.cub.2004.06.054. PubMed: 15268862.
7. Ma XM, Blenis J, (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318. doi:10.1038/nrm2672. PubMed: 19339977.
8. García-Martínez JM, Alessi DR, (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375-385. doi:10.1042/BJ20081668. PubMed: 18925875.
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470.
10. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL, (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27: 1919-1931. doi:10.1038/emboj.2008.119. PubMed: 18566587.
11. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, et al. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27: 1932-1943. doi:10.1038/emboj.2008.120. PubMed: 18566586.
12. Sengupta S, Peterson TR, Sabatini DM, (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322. doi:10.1016/j.molcel.2010.09.026. PubMed: 20965424.
13. Inoki K, Li Y, Zhu T, Wu J, Guan KL, (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657. doi:10.1038/ncb839. PubMed: 12172553.
14. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH, (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323. doi:10.1038/ncb1547. PubMed: 17277771.
15. Mendoza MC, Er EE, Blenis J, (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328. doi:10.1016/j.tibs.2011.03.006. PubMed: 21531565.
16. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP, (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193. doi:10.1016/j.cell.2005.02.031. PubMed: 15851026.
17. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577. doi:10.1074/jbc.M110.159046. PubMed: 21071439.
18. Shah OJ, Wang Z, Hunter T, (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656. doi:10.1016/j.cub.2004.08.026. PubMed: 15380067.
19. Tzatsos A, Kandror KV, (2006) Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76. doi:10.1128/MCB.26.1.63-76.2006. PubMed: 16354680.
20. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332: 1322-1326. doi:10.1126/science.1199484. PubMed: 21659605.
21. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22. doi:10.1016/j.ccr.2007.05.008. PubMed: 17613433.
22. Zhou H, Luo Y, Huang S, (2010) Updates of mTOR inhibitors. Anti Cancer Agents Med Chem 10: 571-581. doi:10.2174/187152010793498663. PubMed: 20812900.
23. Guertin DA, Sabatini DM, (2009) The pharmacology of mTOR inhibition. Sci Signal 2: e24. PubMed: 19383975.
24. Huang S, Houghton PJ, (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371-377. doi:10.1016/S1471-4892(03)00071-7. PubMed: 12901945.
25. Don AS, Zheng XF, (2011) Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 6: 24-35. doi:10.2174/157488711793980147. PubMed: 20868343.
26. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. doi:10.1056/NEJMoa066838. PubMed: 17538086.
27. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, et al. (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610. doi:10.1200/JCO.2007.14.5482. PubMed: 18332469.
28. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595. doi:10.1200/JCO.2007.14.0988. PubMed: 18332470.
29. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468. doi:10.1016/S1097-2765(02)00636-6. PubMed: 12408816.
30. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. doi:10.1158/0008-5472.CAN-05-2925. PubMed: 16452206.
31. Wang X, Yue P, Kim YA, Fu H, Khuri FR, et al. (2008) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68: 7409-7418. doi:10.1158/0008-5472.CAN-08-1522. PubMed: 18794129.
32. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074. PubMed: 18725988.
33. Wei F, Liu Y, Bellail AC, Olson JJ, Sun SY, et al. (2012) K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Lett 322: 58-69. doi:10.1016/j.canlet.2012.02.005. PubMed: 22342683.
34. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E, (2013) Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells. PLOS ONE 8: e57289. doi:10.1371/journal.pone.0057289. PubMed: 23437362.
35. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J, (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 105: 17414-17419. doi:10.1073/pnas.0809136105. PubMed: 18955708.
36. Foster DA, Toschi A, (2009) Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 8: 1026-1029. doi:10.4161/cc.8.7.8044. PubMed: 19270529.
37. Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, et al. (2003) Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res 63: 364-374. PubMed: 12543789.
38. Zhang YJ, Duan Y, Zheng XF, (2011) Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 16: 325-331. doi:10.1016/j.drudis.2011.02.008. PubMed: 21333749.
39. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032. doi:10.1074/jbc.M900301200. PubMed: 19150980.
40. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLOS Biol 7: e38. doi:10.1371/journal.pbio.1000038. PubMed: 19209957.
41. Janes MR, Limon JJ, So L, Chen J, Lim RJ, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213. doi:10.1038/nm.2091. PubMed: 20072130.
42. Li H, Lin J, Wang X, Yao G, Wang L, et al. (2012) Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat 134: 1057-1066. doi:10.1007/s10549-012-2036-2. PubMed: 22476852.
43. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, et al. (2012) Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 120: 2679-2689. doi:10.1182/blood-2011-11-393934. PubMed: 22826565.
44. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, et al. (2009) Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 15: 7207-7216. doi:10.1158/1078-0432.CCR-09-1249. PubMed: 19934294.
45. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, et al. (2009) mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 16: 2617-2628. doi:10.1245/s10434-009-0555-9. PubMed: 19517193.
46. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, et al. (1999) Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18: 2507-2517. doi:10.1038/sj.onc.1202563. PubMed: 10229202.
47. Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, et al. (2012) Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 12: 86. doi:10.1186/1471-2407-12-86. PubMed: 22401294.
48. Zhang Y, Zheng XF, (2012) mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 11: 594-603. doi:10.4161/cc.11.3.19096. PubMed: 22262166.
49. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886. doi:10.1016/j.cell.2009.03.046. PubMed: 19446321.
50. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C, (2012) A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2: 140-155. doi:10.1158/2159-8290.CD-11-0172 PubMed: 22585859.
51. Schmelzle T, Hall MN, (2000) TOR, a central controller of cell growth. Cell 103: 253-262. doi:10.1016/S0092-8674(00)00117-3. PubMed: 11057898.
52. Vlahos CJ, Matter WF, Hui KY, Brown RF, (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248. PubMed: 8106507.
53. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11: 317-328. doi:10.1158/1535-7163.MCT-11-0474. PubMed: 22188813.
54. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, et al. (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2: 1036-1047. doi:10.1158/2159-8290.CD-11-0348 PubMed: 22915752.
55. Li B, Gao S, Wei F, Bellail AC, Hao C, et al. (2012) Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. Oncol Rep 28: 15-20. PubMed: 22552366.
56. Altomare I, Hurwitz H, (2013) Everolimus in colorectal cancer. Expert Opin Pharmacother 14: 505-513. doi:10.1517/14656566.2013.770473. PubMed: 23406528.
57. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51. doi:10.1016/j.ccr.2010.05.023. PubMed: 20609351.
58. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134. doi:10.1016/j.cell.2010.06.011. PubMed: 20602996.
59. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, et al. (2012) The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 287: 21796-21805. doi:10.1074/jbc.M111.304626. PubMed: 22556409.
60. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354. doi:10.1038/nrc1609. PubMed: 15864276.
61. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286. doi:10.1016/S1470-2045(05)70102-9. PubMed: 15863375.
62. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345. doi:10.1056/NEJMoa033025. PubMed: 15269313.
63. Hezel AF, Ryan DP, (2007) Emerging therapies for colorectal cancer. Expert Opin Investig Drugs 16: 867-876. doi:10.1517/13543784.16.6.867. PubMed: 17501698.
64. Townsley CA, Major P, Siu LL, Dancey J, Chen E, et al. (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94: 1136-1143. doi:10.1038/sj.bjc.6603055. PubMed: 16570047.
65. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, et al. (2007) Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 18: 1185-1189. doi:10.1093/annonc/mdm124. PubMed: 17483115.
66. Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, et al. (2009) Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 8: 38-42. doi:10.3816/CCC.2009.n.006. PubMed: 19203895.
67. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, et al. (2006) Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 24: 1892-1897. doi:10.1200/JCO.2005.05.3728. PubMed: 16622264.
68. Bajetta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Dotti KF, et al. (2009) Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer Chemother Pharmacol 64: 67-72. doi:10.1007/s00280-008-0852-1. PubMed: 18936940.
69. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, et al. (2012) Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 30: 1505-1512. doi:10.1200/JCO.2011.38.6599. PubMed: 22412142.